EA200200078A1 - Птеридиноны в качестве ингибиторов киназ - Google Patents

Птеридиноны в качестве ингибиторов киназ

Info

Publication number
EA200200078A1
EA200200078A1 EA200200078A EA200200078A EA200200078A1 EA 200200078 A1 EA200200078 A1 EA 200200078A1 EA 200200078 A EA200200078 A EA 200200078A EA 200200078 A EA200200078 A EA 200200078A EA 200200078 A1 EA200200078 A1 EA 200200078A1
Authority
EA
Eurasian Patent Office
Prior art keywords
substituted
hydrogen
compounds
lower alkyl
members
Prior art date
Application number
EA200200078A
Other languages
English (en)
Other versions
EA005287B1 (ru
Inventor
Уильям Эликзэндер Денни
Эллен Майра Добрусин
Джеймс Бернард Крамер
Деннис Джозеф Мак Намара
Гордон Уильям Рукасл
Хауард Дэниэл Холлис Шоуолтер
Питер Лоренс Тугуд
Original Assignee
Уорнер-Ламберт Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Уорнер-Ламберт Компани filed Critical Уорнер-Ламберт Компани
Publication of EA200200078A1 publication Critical patent/EA200200078A1/ru
Publication of EA005287B1 publication Critical patent/EA005287B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • AIDS & HIV (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)

Abstract

Описаны соединения формул (Ia), (Ib), (Ic), (Id), где W представляет собой NH, S, SO или SO; Rпредставляет собой (не)замещенный арил, (не)замещенный гетероарил или (не)замещенный карбоцикл или гетероцикл; Q представляет собой водород или низший алкил; Rи Rявляются одинаковыми или разными и представляют собой водород, галоген, низший алкил, низший алкокси, (не)замещенный арил, (не)замещенный гетероарил, (не)замещенный арилалкил или (не)замещенный гетероарилалкил; а Rпредставляет собой водород, низший алкил или (не)замещенную карбоциклическую группу, содержащую от 3 до 7 членов, из которых до двух членов возможно представляют собой гетероатомы, выбранные из кислорода и азота; либо Rпредставляет собой (не)замещенный арил, (не)замещенный гетероарил, (не)замещенный арилалкил или (не)замещенный гетероарилалкил. Эти соединения полезны для лечения клеточных пролиферативных расстройств, таких как рак и рестеноз. Эти соединения являются сильнодействующими ингибиторами циклинзависимых киназ (cdk) и фактор роста-опосредуемых киназ. В соответствии с настоящим изобретением также предложен способ лечения клеточных пролиферативных расстройств. Также в соответствии с настоящим изобретением предложена фармацевтически приемлемая композиция, содержащая соединение формулы (I).Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200200078A 1999-09-15 2000-06-21 Птеридиноны в качестве ингибиторов киназ EA005287B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15409599P 1999-09-15 1999-09-15
PCT/US2000/017037 WO2001019825A1 (en) 1999-09-15 2000-06-21 Pteridinones as kinase inhibitors

Publications (2)

Publication Number Publication Date
EA200200078A1 true EA200200078A1 (ru) 2002-12-26
EA005287B1 EA005287B1 (ru) 2004-12-30

Family

ID=22549985

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200200078A EA005287B1 (ru) 1999-09-15 2000-06-21 Птеридиноны в качестве ингибиторов киназ

Country Status (29)

Country Link
US (2) US7169778B2 (ru)
EP (1) EP1409487A1 (ru)
JP (1) JP2003509425A (ru)
KR (1) KR20020027649A (ru)
CN (1) CN1373763A (ru)
AP (1) AP2002002479A0 (ru)
AU (1) AU777468B2 (ru)
BG (1) BG106594A (ru)
BR (1) BR0013952A (ru)
CA (1) CA2393896A1 (ru)
CR (1) CR6586A (ru)
CZ (1) CZ2002846A3 (ru)
DZ (1) DZ3186A1 (ru)
EA (1) EA005287B1 (ru)
EE (1) EE200200140A (ru)
HK (1) HK1048992A1 (ru)
HU (1) HUP0202713A3 (ru)
IL (1) IL148614A0 (ru)
IS (1) IS6298A (ru)
MA (1) MA26819A1 (ru)
MX (1) MXPA02001108A (ru)
NO (1) NO20021239D0 (ru)
NZ (1) NZ516872A (ru)
OA (1) OA12010A (ru)
PL (1) PL353269A1 (ru)
SK (1) SK3542002A3 (ru)
WO (1) WO2001019825A1 (ru)
YU (1) YU18502A (ru)
ZA (1) ZA200200896B (ru)

Families Citing this family (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7276506B2 (en) 1998-12-28 2007-10-02 4 Aza Bioscience Nv Immunosuppressive effects of pteridine derivatives
SE9903544D0 (sv) * 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
GB2359081A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines
GB2359078A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB2359551A (en) * 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
SE0003828D0 (sv) 2000-10-20 2000-10-20 Astrazeneca Ab Novel compounds
US6858608B2 (en) * 2001-01-09 2005-02-22 Aventis Pharma S.A. Chemical derivatives and their application as antitelomerase agents
US6887873B2 (en) 2001-03-23 2005-05-03 Aventis Pharma S.A. Triazine derivatives and their application as antitelomerase agents
WO2002076985A1 (en) * 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
SE0101322D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab Novel compounds
CA2446939C (en) * 2001-05-16 2005-08-02 Matthias Stein-Gerlach Pyridylpyrimidine derivatives as effective compounds against prion diseases
CA2451128A1 (en) * 2001-06-26 2003-01-09 Bristol-Myers Squibb Company N-heterocyclic inhibitors of tnf-alpha expression
SE0102716D0 (sv) * 2001-08-14 2001-08-14 Astrazeneca Ab Novel compounds
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
US7115617B2 (en) 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
US6806272B2 (en) 2001-09-04 2004-10-19 Boehringer Ingelheim Pharma Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
EA007062B1 (ru) * 2001-09-04 2006-06-30 Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг Новые дигидроптеридиноны, способы их получения и их применение в качестве лекарственных средств
DK1438053T3 (da) * 2001-10-17 2008-12-08 Boehringer Ingelheim Pharma Pyrimidinderivater, lægemiddel indeholdende disse forbindelser, deres anvendelse og fremgangsmåder til deres fremstilling
EP1453516A2 (de) 2001-10-17 2004-09-08 Boehringer Ingelheim Pharma GmbH & Co.KG 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren
ATE314370T1 (de) 2002-01-22 2006-01-15 Warner Lambert Co 2-(pyridin-2-ylamino)-pyrido(2,3-d)pyrimidin-7- one
DE10212100A1 (de) * 2002-03-11 2003-10-23 Schering Ag CDK inhibitorische 2-Heteroaryl-Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
US7196090B2 (en) * 2002-07-25 2007-03-27 Warner-Lambert Company Kinase inhibitors
ATE360015T1 (de) * 2002-07-31 2007-05-15 Critical Outcome Technologies Protein tyrosin kinase inhibitoren
GB0221829D0 (en) * 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
GB0221828D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
US7067658B2 (en) * 2002-09-30 2006-06-27 Bristol-Myers Squibb Company Pyridino and pyrimidino pyrazinones
EP2039683B1 (en) * 2002-10-03 2012-12-19 Targegen, Inc. Vasculostatic agents and methods of use thereof
ATE380810T1 (de) * 2002-10-09 2007-12-15 Critical Outcome Technologies Protein-tyrosine-kinase-inhibitoren
KR20050084027A (ko) * 2002-11-28 2005-08-26 쉐링 악티엔게젤샤프트 Ｃｈｋ-, ｐｄｋ- 및 ａｋｔ-억제성 피리미딘, 그의제조방법 및 약제로서의 그의 용도
MXPA05007503A (es) * 2003-01-17 2005-09-21 Warner Lambert Co Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular.
US7157455B2 (en) 2003-02-10 2007-01-02 Hoffmann-La Roche Inc. 4-Aminopyrimidine-5-one derivatives
CA2517020C (en) * 2003-02-26 2012-06-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, method for the production and use thereof in the form of drugs
US6861422B2 (en) * 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
CN102358738A (zh) 2003-07-30 2012-02-22 里格尔药品股份有限公司 2,4-嘧啶二胺化合物及其预防和治疗自体免疫疾病的用途
GB0328243D0 (en) * 2003-12-05 2004-01-07 Astrazeneca Ab Methods
US7405220B2 (en) 2004-06-09 2008-07-29 Hoffmann-La Roche Inc. Pyrazolopyrimidines
DE102004029784A1 (de) * 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
CA2570494A1 (en) * 2004-06-23 2006-01-05 Irm Llc Pteridine derivatives as protein kinase inhibitors
DE102004033670A1 (de) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
US7423051B2 (en) 2004-07-15 2008-09-09 Hoffmann-La Roche Inc. 2,6-diaminopyridine derivatives
US7423053B2 (en) 2004-07-15 2008-09-09 Hoffmann-La Roche Inc. 4-Aminothiazole derivatives
DE102004034623A1 (de) * 2004-07-16 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 6-Formyl-tetrahydropteridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US7728134B2 (en) * 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060074088A1 (en) * 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US7759485B2 (en) * 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US20060035903A1 (en) * 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
EP1630163A1 (de) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1632493A1 (de) 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
JP2008510770A (ja) * 2004-08-26 2008-04-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｌｋ阻害剤としての新規プテリジノン
JP2008510771A (ja) * 2004-08-27 2008-04-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ジヒドロプテリジノン、その製造方法および医薬薬剤としてのその使用
DE102004058337A1 (de) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
EP1828186A1 (en) * 2004-12-13 2007-09-05 Sunesis Pharmaceuticals, Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors
US7713987B2 (en) 2005-12-06 2010-05-11 Rigel Pharmaceuticals, Inc. Pyrimidine-2,4-diamines and their uses
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
AU2007215221C1 (en) 2006-02-14 2013-05-30 Vertex Pharmaceuticals Incorporated Dihydrodiazepines useful as inhibitors of protein kinases
TW200808805A (en) * 2006-04-12 2008-02-16 Vertex Pharma Tetrahydropteridines useful as inhibitors of protein kinases
CN101448830A (zh) * 2006-05-19 2009-06-03 阿斯利康(瑞典)有限公司 作为抗增殖剂的二氢碟啶化合物
WO2008009909A1 (en) * 2006-07-17 2008-01-24 Astrazeneca Ab Pteridimones as modulators of polo-like kinase
WO2008009078A2 (en) 2006-07-20 2008-01-24 Gilead Sciences, Inc. 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
US10144736B2 (en) 2006-07-20 2018-12-04 Gilead Sciences, Inc. Substituted pteridines useful for the treatment and prevention of viral infections
WO2008040951A1 (en) * 2006-10-03 2008-04-10 Astrazeneca Ab Compounds
US7893066B2 (en) 2006-10-05 2011-02-22 Gilead Palo Alto, Inc. Pyridol[2,3-B]pyrazinones for use as stearoyl CoA desaturase inhibitors
CN101522676A (zh) 2006-10-05 2009-09-02 Cv医药有限公司 用作硬脂酰-CoA脱氢酶抑制剂的双环含氮杂环化合物
CA2673683C (en) 2007-01-11 2014-07-29 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
EP1953163A1 (en) 2007-02-01 2008-08-06 Boehringer Ingelheim Pharma GmbH & Co. KG Pteridinone derivatives as PI3-kinases inhibitors
JP2010523653A (ja) 2007-04-09 2010-07-15 ギリアード・パロ・アルト・インコーポレイテッド ステアロイルＣｏＡデサチュラーゼのインヒビターとして使用するためのプテリジノン誘導体
EP3098223A1 (en) * 2007-08-03 2016-11-30 Boehringer Ingelheim International GmbH Crystalline form of a dihydropteridione derivative
US20110201818A1 (en) 2007-09-25 2011-08-18 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
JP5400791B2 (ja) 2007-12-04 2014-01-29 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 置換ジヒドロプテリジン−６−オン誘導体、その製造方法及びキナーゼ阻害剤としてのその使用
CA2710039C (en) 2007-12-26 2018-07-03 Critical Outcome Technologies, Inc. Semicarbazones, thiosemicarbazones and related compounds and methods for treatment of cancer
JP2011516498A (ja) 2008-04-04 2011-05-26 ギリアード サイエンシーズ， インコーポレイテッド ステアロイル−ＣｏＡデサチュラーゼの阻害剤として使用するためのトリアゾロピリジノン誘導体
CA2730890C (en) 2008-07-17 2018-05-15 Critical Outcome Technologies Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
AU2009333559B2 (en) 2008-12-09 2015-03-12 Gilead Sciences, Inc. Modulators of toll-like receptors
ES2661850T3 (es) 2009-09-14 2018-04-04 Gilead Sciences, Inc. Moduladores de receptores del tipo toll
CN102020643A (zh) 2009-09-22 2011-04-20 上海恒瑞医药有限公司 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用
NZ599342A (en) 2009-09-25 2014-04-30 Vertex Pharma Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
SG179206A1 (en) 2009-09-25 2012-04-27 Vertex Pharma Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
WO2011050245A1 (en) * 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
US20120329803A1 (en) 2010-02-17 2012-12-27 Boehringer Ingelheim International Gmbh Dihydropteridinones, method for production and use thereof
CA2794952C (en) 2010-04-01 2018-05-15 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
WO2013071217A1 (en) * 2011-11-10 2013-05-16 OSI Pharmaceuticals, LLC Dihydropteridinones
DE112013002484B4 (de) 2012-05-14 2023-05-04 Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. Pteridinketon-Derivat und Anwendungen desselben als EGFR-, BLK- und FLT3-Inhibitor
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
JP6576325B2 (ja) 2013-03-15 2019-09-18 セルジーン シーエーアール エルエルシー ヘテロアリール化合物およびそれらの使用
CA2907243C (en) 2013-03-15 2021-12-28 Celgene Avilomics Research, Inc. Substituted dihydropyrimidopyrimidinone compounds and pharmaceutical compositions thereof use fgfr4 inhibitor
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
WO2015011236A1 (en) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome
MA39784B1 (fr) 2014-03-26 2021-03-31 Astex Therapeutics Ltd Combinaisons des inhibiteurs du fgfr et du cmet destinées au traitement du cancer
AU2015238305B2 (en) 2014-03-26 2020-06-18 Astex Therapeutics Ltd Combinations of an FGFR inhibitor and an IGF1R inhibitor
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
WO2015193228A1 (de) * 2014-06-19 2015-12-23 Bayer Pharma Aktiengesellschaft Bet-proteininhibitorische 1,4-dihydropyrido[3,4-b]pyrazinone mit para-substituierter aromatischer amino- oder ethergruppe
TWI733652B (zh) 2014-07-11 2021-07-21 美商基利科學股份有限公司 用於治療ＨＩＶ之ｔｏｌｌ樣受體調節劑
JP2017526730A (ja) 2014-09-16 2017-09-14 ギリアード サイエンシーズ， インコーポレイテッド Ｔｏｌｌ様受容体モジュレーターの固体形態
US9573952B2 (en) 2014-09-16 2017-02-21 Gilead Sciences, Inc. Methods of preparing toll-like receptor modulators
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
JO3695B1 (ar) 2015-02-10 2020-08-27 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n- (3.5- ثنائي ميثوكسي فينيل)-n-(1-ميثيل إيثيل)-n- 3-( ميثيل-h1-بيرازول-4-يل) كينوكسالين-6-يل) إيثان- 1.2-ثنائي الأمين)
DK3097102T3 (en) 2015-03-04 2018-01-22 Gilead Sciences Inc TOLL-LIKE RECEPTOR MODULATING 4,6-DIAMINO-PYRIDO [3,2-D] PYRIMIDINE COMPOUNDS
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
CN106279173A (zh) * 2015-05-29 2017-01-04 华东理工大学 蝶啶酮衍生物作为egfr抑制剂的应用
CN108137546B (zh) 2015-09-23 2021-07-27 詹森药业有限公司 双杂芳基取代的1,4-苯并二氮杂卓化合物及其用于治疗癌症的用途
KR102703498B1 (ko) 2015-09-23 2024-09-04 얀센 파마슈티카 엔브이 신규 화합물
CN106892922B (zh) * 2015-12-18 2019-04-19 华东理工大学 作为egfr抑制剂的5,8-二氢蝶啶-6,7-二酮衍生物及其应用
CN107151249B (zh) * 2016-03-04 2020-08-14 华东理工大学 作为flt3抑制剂的蝶啶酮衍生物及应用
MA46093A (fr) 2016-09-02 2021-05-19 Gilead Sciences Inc Composés modulateurs du recepteur de type toll
WO2018045150A1 (en) 2016-09-02 2018-03-08 Gilead Sciences, Inc. 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
CN108721298A (zh) * 2017-04-19 2018-11-02 华东理工大学 作为布鲁顿酪氨酸激酶抑制剂的嘧啶并杂环化合物及其应用
WO2020033823A1 (en) * 2018-08-10 2020-02-13 Yale University Small-molecule pi5p4k alpha/beta inhibitors and methods of treatment using same
TWI831829B (zh) 2018-09-12 2024-02-11 美商建南德克公司 苯氧基-吡啶基-嘧啶化合物及使用方法
CN111217815B (zh) * 2018-11-27 2021-06-18 沈阳药科大学 含有喋啶酮骨架的化合物及其制备方法和应用
JP7539892B2 (ja) * 2019-01-03 2024-08-26 ジェネンテック， インコーポレイテッド 癌疾患の処置のためのエンドリボヌクレアーゼのイノシトール要求酵素ｉ（ｉｒｅｉアルファ）の阻害剤としてのピリド－ピリミジノン化合物及びプテリジノン化合物
TW202212339A (zh) 2019-04-17 2022-04-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
KR20220011685A (ko) 2019-05-22 2022-01-28 길리애드 사이언시즈, 인코포레이티드 Tlr7 조절 화합물과 hiv 백신의 조합
TWI879779B (zh) 2019-06-28 2025-04-11 美商基利科學股份有限公司 類鐸受體調節劑化合物的製備方法
CN110357885A (zh) * 2019-07-24 2019-10-22 江南大学 一种蝶啶类化合物及其在药学上的应用
CN113801118A (zh) * 2020-06-12 2021-12-17 华东理工大学 作为rsk抑制剂的蝶啶酮衍生物及其应用
WO2022177302A1 (ko) * 2021-02-17 2022-08-25 보령제약 주식회사 Dna-pk 억제 활성을 갖는 피리미딘-융합 고리 화합물 및 이의 용도
CN113087708A (zh) * 2021-04-06 2021-07-09 南方医科大学 一种蝶啶酮类化合物及其应用
CN115850282A (zh) * 2021-09-24 2023-03-28 华东理工大学 靶向降解egfr蛋白的化合物及其制备方法和应用
CN115010711B (zh) * 2022-07-12 2024-12-03 江南大学 一种蝶啶7（8h）-酮类化合物及其在药学上的应用
CN118047779B (zh) * 2022-11-09 2025-02-11 沈阳药科大学 含苯联杂芳基的二氢喋啶酮衍生物及其用途
WO2024199388A1 (zh) * 2023-03-29 2024-10-03 微境生物医药科技(上海)有限公司 作为myt1抑制剂的化合物
WO2026024674A1 (en) 2024-07-22 2026-01-29 Genesis Therapeutics, Inc. Methods of treating skp2-associated cancers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS53124296A (en) * 1977-04-05 1978-10-30 Mitsubishi Chem Ind Ltd Penicillin derivatives
US6395733B1 (en) * 1995-06-07 2002-05-28 Pfizer Inc Heterocyclic ring-fused pyrimidine derivatives
EP0831829B1 (en) * 1995-06-07 2003-08-20 Pfizer Inc. Heterocyclic ring-fused pyrimidine derivatives
EP0837063A1 (en) * 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
JPH1180131A (ja) * 1997-09-01 1999-03-26 Mitsubishi Chem Corp エチニルピリミジン誘導体
WO2002076985A1 (en) * 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases

Also Published As

Publication number Publication date
OA12010A (en) 2006-04-19
CR6586A (es) 2004-02-02
IS6298A (is) 2002-03-13
AU5629500A (en) 2001-04-17
MA26819A1 (fr) 2004-12-20
US20030130286A1 (en) 2003-07-10
EA005287B1 (ru) 2004-12-30
NZ516872A (en) 2003-10-31
JP2003509425A (ja) 2003-03-11
HUP0202713A2 (hu) 2002-12-28
CA2393896A1 (en) 2001-03-22
WO2001019825A1 (en) 2001-03-22
NO20021239L (no) 2002-03-13
AU777468B2 (en) 2004-10-21
BR0013952A (pt) 2002-05-14
MXPA02001108A (es) 2002-08-20
IL148614A0 (en) 2002-09-12
SK3542002A3 (en) 2003-04-01
US20070049600A1 (en) 2007-03-01
BG106594A (en) 2002-12-29
EE200200140A (et) 2003-04-15
CZ2002846A3 (cs) 2003-02-12
HK1048992A1 (zh) 2003-04-25
AP2002002479A0 (en) 2002-06-30
NO20021239D0 (no) 2002-03-13
YU18502A (sh) 2004-12-31
EP1409487A1 (en) 2004-04-21
DZ3186A1 (fr) 2001-03-22
ZA200200896B (en) 2003-07-30
PL353269A1 (en) 2003-11-03
KR20020027649A (ko) 2002-04-13
CN1373763A (zh) 2002-10-09
HUP0202713A3 (en) 2005-02-28
US7169778B2 (en) 2007-01-30

Similar Documents

Publication Publication Date Title
YU18502A (sh) Pteridinoni kao inhibitori kinaza
EA200001171A1 (ru) Бициклические пиримидины и бициклические 3,4-дигидропиримидины как ингибиторы клеточной пролиферации
IL79911A (en) Heterocyclic-substituted indoles,process for the preparation thereof and pharmaceutical compositions containing them
EE200200148A (et) Kinasoliini derivaadid, nende valmistamise meetodning kasutamine
DE60226912D1 (de) Chinolin- und Chianzolinderivate zur Behandlung von Tumoren
CA2321639A1 (en) Bicyclo[2.2.1]heptanes and related compounds
DE60128343D1 (de) Pyrimidine verbindungen
EA200100755A1 (ru) 4-оксо-1,4-дигидро-3-хинолинкарбоксамиды как антивирусные агенты
ATE175962T1 (de) Anilin derivate
BR0013041A (pt) Composto heterociclico e composição farmacêutica para tratar e prevenir doenças mediadas por cgmp-pde, seu uso e método
RU94043324A (ru) Гетеробициклические соединения
CA1272482C (en) QUINOLINECARBOXYLIC ACID DERIVATIVES
PE20020524A1 (es) 7-oxo-piridopirimidinas como inhibidores de quinasas
EA200400475A1 (ru) Замещенные производные бензимидазола и их применение для лечения злокачественной опухоли
NO964698L (no) Bicykliske aminderivater som inhibitorer av nitrogenoksid-syntetase
ES2001875A6 (es) Procedimiento para preparar nuevos derivados de aminoacidos
EA200200523A1 (ru) Новые разветвленные замещенные аминопроизводные 3-амино-1-фенил-1h[1,2,4]триазола, способы их получения и содержащие их фармацевтические композиции
EA200400469A1 (ru) Замещенные производные алкиламинопиридазинона, способ их получения и содержащие их фармацевтические композиции
ES2055651A1 (es) Procedimiento para la obtencion de nuevas amidinas derivadas de 3-aminoetilindoles.
ES500810A0 (es) Procedimiento de preparacion de aminoalcoxipirazoles
EA200200379A3 (ru) Новые соединения пиримидин-4-она, способ их получения и содержащие их фармацевтические композиции
DE60006944D1 (de) Verfahren und zusammensetzungen zur behandlung von leukämie
ES552874A0 (es) Un procedimiento para preparar benzo (c)-1,5-naftiridinas
GB9904377D0 (en) The preparation of chiral derivatives
CO4770972A1 (es) Proceso para preparar derivados de 5-fenoxi quinoleina

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU